Literature DB >> 8717440

Effect of interleukin-1 receptor antagonist (IL-1RA) on histamine and serotonin release by rat basophilic leukemia cells (RBL-2H3) and peritoneal mast cells.

P Conti1, W Bouchet, C Feliciani, S Mammarella, L Kudchadker, R C Barbacane, M Reale, I Haggag, G Bruneau, J Thibault, T C Theoharides.   

Abstract

Recently, it has been appreciated that cultured mast cells are significant sources of cytokines. However, the role of interkeukin-1 (IL-1) on mast cells and/or basophil degranulation is still unclear. In this report we provide evidence that rat basophilic leukemia cells (RBLC) cultured with a natural inhibitor of IL-1, interleukin-1 receptor antagonist (IL-1RA) (500 ng/ml) for 48 h, strongly inhibited the spontaneous release of serotonin (5HT) and histamine (from 22.50 to 43.49%), compared to untreated cells (control). When IL-1RA-treated and untreated RBLC were stimulated with a secretagogue (anti-IgE), no difference was found in the percent of 5HT and histamine release. Moreover, in another set of experiments using rat peritoneal mast cells (RPMC) treated and untreated with IL-1RA, we found that IL-1RA did not affect the release of 5HT or histamine, even when the secretagogue anti-IgE or compound 48/80 (C48/80) were used. The present studies describe an additional biological activity of IL-1RA, inhibiting histamine and 5HT release from RBLC cultures.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8717440     DOI: 10.1007/BF00714334

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  32 in total

1.  Macrophage down-regulation by interleukin-1 receptor antagonist.

Authors:  P Conti; R A Dempsey
Journal:  Am J Hematol       Date:  1992-04       Impact factor: 10.047

Review 2.  Activation of functionally distinct subsets of CD4+ T lymphocytes.

Authors:  M E Williams; T L Chang; S K Burke; A H Lichtman; A K Abbas
Journal:  Res Immunol       Date:  1991-01

3.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

4.  In vitro histamine release from basophils of asthmatic and atopic individuals in D2O.

Authors:  R Tung; L M Lichtenstein
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

5.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.

Authors:  D B Carter; M R Deibel; C J Dunn; C S Tomich; A L Laborde; J L Slightom; A E Berger; M J Bienkowski; F F Sun; R N McEwan
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

6.  A histamine-releasing factor from activated human mononuclear cells.

Authors:  A P Kaplan; M Haak-Frendscho; A Fauci; C Dinarello; E Halbert
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

7.  Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans.

Authors:  C A Dinarello; L J Rosenwasser; S M Wolff
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

8.  Inhibition of interleukin-1 beta mRNA expression and interleukin-1 alpha and beta secretion by a specific human recombinant interleukin-1 receptor antagonist in human peripheral blood mononuclear cells.

Authors:  P Conti; C Feliciani; R C Barbacane; M R Panara; M Reale; F C Placido; D N Sauder; R A Dempsey; P Amerio
Journal:  Immunology       Date:  1992-10       Impact factor: 7.397

9.  A urine inhibitor of interleukin 1 activity that blocks ligand binding.

Authors:  P Seckinger; J W Lowenthal; K Williamson; J M Dayer; H R MacDonald
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

10.  Secretion in mast cells induced by calcium entrapped within phospholipid vesicles.

Authors:  T C Theoharides; W W Douglas
Journal:  Science       Date:  1978-09-22       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.